[1]艾丁丁,罗伟生△,蒋云霞.动物肝纤维化模型建立研究进展*[J].陕西医学杂志,2020,49(7):907-909.[doi:DOI:10.3969/j.issn.10007377.2020.07.038]
　AI Dingding,LUO Weisheng,JIANG Yunxia..Progress in the establisment of animal liver fibrosis model[J].,2020,49(7):907-909.[doi:DOI:10.3969/j.issn.10007377.2020.07.038]
点击复制

动物肝纤维化模型建立研究进展*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年7期
页码:
907-909
栏目:
综述
出版日期:
2020-07-05

文章信息/Info

Title:
Progress in the establisment of animal liver fibrosis model
作者:
艾丁丁; 罗伟生△; 蒋云霞
广西中医药大学( 南宁530000)
Author(s):
AI Dingding; LUO Weisheng; JIANG Yunxia.
Guangxi University of Chinese Medicine(Nanning 530000)
关键词:
肝纤维化;  肝星状细胞;  大鼠;  四氯化碳;  动物模型;  肝硬化;  综述
Keywords:
Liver fibrosis;  Hepatic stellate cell;  Rat;  Carbon tetrachloride;  Animal model;  Liver cirrhosis;  Overview
分类号:
R575.2
DOI:
DOI:10.3969/j.issn.10007377.2020.07.038
文献标志码:
A
摘要:
目前,慢性肝病有着在全球蔓延的趋势,而阻止慢性肝病转向肝硬化、肝癌的最预效的办法就是阻断其中心环节肝纤维化的发展。因此,运用动物实验建立肝纤维化模型,研究清楚肝纤维化的机制并研制出合理的药物,能有效阻断肝病的发展进程。现代,常用的是运用大鼠、家兔或者小鼠建立肝病模型,而最常用的是大鼠。因此,本文主要介绍了运用大鼠建立动物肝纤维化模型,为研究肝纤维化的进程和新药治疗肝纤维化提供参考。
Abstract:
At present,chronic liver disease is expanding their range around the world,but the most effective way to prevent chronic liver disease from turning to liver cirrhosis and hepatocellular carcinoma is to block development of liver fibrosis. Therefore,using animal experiments to establish liver fibrosis model,researching the mechanism of liver fibrosis and developing reasonable drugs can effectively block the development of liver disease. Now,rats,rabbits or mice are often used to establish liver disease models,but the most commonly used is rats. Hence,this paper mainly introduces the establishment of animal liver fibrosis model with rats,which with provides reference for the study of the process of liver fibrosis and the treatment of liver fibrosis with new drugs.

参考文献/References:

[1] 姜 娜,平 键,徐列明.肝星状细胞的活化机制—探寻肝纤维化新的诊断指标和治疗靶点[J].临床肝胆病杂志,2019,35(3):640-643.
[2] Pierantonelli I,Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH [J].Transplantation,2019,103(1):e1-e13.
[3] 王宪东,石安华,陈文玲.肝纤维化大鼠模型的研究进展[J].世界最新医学信息文摘,2016,16(94): 30,39.
[4] Tsay HC,Yuan Q,Balakrishnan A,et al.Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis.[J].J Hepatol,2019,70(4):722-734
[5] 付洪彦,龚作炯.肝纤维化的发生机制及其诊疗研究进展[J].中西医结合肝病杂志,2018,28(2):125-128.
[6] 尹连红,于 浩,彭金咏.四氯化碳诱导肝损伤的分子机制及中药干预的研究进展[J].中国现代应用药学,2015,32(9):1147-1155.
[7] 崔承虎,韩明子,金世柱,等.肝硬化动物模型造模方法的研究进展[J].现代生物医学进展,2015,15(12):2393-2396.
[8] Cheng Y,Mai JY,Wang MF,et al. Antifibrotic effect of total flavonoids ofAstmgali Radixon dimethylnitrosamine-induced liver cirrhosis in rats[J]. Chinese Journal of Integrative Medicine,2017,23(1):48-54.
[9] 边艳琴,曹红燕,李建缘,等.脂肪酸代谢异常是二甲基亚硝胺诱导的大鼠肝纤维化发病机制之一[J].世界科学技术-中医药现代化,2016,18(2):241-249.
[10] 周 恒,李 俊,王 华.酒精性肝病动物模型研究进展[J].中国药理学通报,2016,32(4):468-472.
[11] Louvet A,Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment[J]. Nature Reviews Gastroenterology & Hepatology,2015,12(4):231-242.
[12] 信丰智,范建高.欧洲非酒精性脂肪性肝病诊疗指南简介[J].实用肝脏病杂志,2016,19(4):519-520.
[13] Fan JG,Kim SU,Wong VW. New Trends on obesity and NAFLD in Asia[ J]. J Hepatol,2017,67(4): 862-873.
[14] 程贤文,张 博,万文雅,等.脂肪性肝病中西医研究进展[J].中国中西医结合消化杂志,2019,27(4):318-322.
[15] 刘 欣,齐永芬,鱼艳荣.血吸虫病肝纤维化中可溶性虫卵抗原对肝星状细胞的作用[J].中国寄生虫学与寄生虫病杂志,2019,37(2):218-222.
[16] 邵伟姝. AKF-PD治疗血吸虫诱导小鼠肝纤维化的疗效研究[D].长沙:中南大学,2011.
[17] 孔庆明. 青蒿琥酯抗血吸虫性肝纤维化的作用研究[C]//. 中国动物学会寄生虫学专业委员会.第十一届全国寄生虫学青年工作者学术研讨会摘要集.北京:中国动物学会寄生虫学专业委员会,2018:89.
[18] 王福根,梁伟峰,席建军,等.非酒精性脂肪性肝炎动物模型的建立与应用[J].中国临床药理学与治疗学,2015,20(7):835-840.
[19] 盖曲倞,董凌月,安 威.非酒精性脂肪性肝炎及肝纤维化动物模型的建立[J].胃肠病学和肝病学杂志,2016,25(5):562-565.
[20] Maeso-Díaz R,Ortega-Ribera M,Lafoz E,et al.Aging influences hepatic microvascular biology and liver fibrosis in advanced chronic liver disease[J].Aging Dis,2019,10(4):684-698.

相似文献/References:

[1]蔡碧莲,文亦磊△,罗伟生△.大鼠肝纤维化实验动物模型的构建*[J].陕西医学杂志,2020,49(6):659.[doi:DOI:10.3969/j.issn.10007377.2020.06.005]
[2]刘翔宇,王凌云.环杷明抑制肝星形细胞激活改善肝纤维化作用实验研究*[J].陕西医学杂志,2020,49(6):663.[doi:DOI:10.3969/j.issn.10007377.2020.06.006]
　LIU Xiangyu,WANG Lingyun..Effect of cyclopamine on inhibiting the activation of hepatic astrocyte and improving hepatic fibrosis[J].,2020,49(7):663.[doi:DOI:10.3969/j.issn.10007377.2020.06.006]
[3]韩艳珍,单铁英,李 伟,等.口服枸杞多糖对小鼠肝纤维化组织基质金属蛋白酶-2及基质金属蛋白酶-2抑制剂水平影响的实验研究[J].陕西医学杂志,2021,50(3):276.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.005]
　HAN Yanzhen,SHAN Tieying,LI Wei,et al.Effects of Lycium barbarum polysaccharide on the levels of MMP-2 and TIMP-2 in mice with liver fibrosis[J].,2021,50(7):276.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.005]
[4]姜 帆,李春香,李忠原.超声双模态影像技术联合动态增强磁共振检查对大鼠早期肝纤维化的评估价值实验研究[J].陕西医学杂志,2023,52(3):273.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.006]
　JIANG Fan,LI Chunxiang,LI Zhongyuan.Evaluation value of ultrasound dual-modality imaging technique combined with DCE-MRI in rats with early hepatic fibrosis[J].,2023,52(7):273.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.006]
[5]郝礼森,潘恩亮,季景秀,等.含SH2结构域蛋白酪氨酸磷酸酶2表达变化对肝纤维化大鼠肝组织中细胞外信号调节激酶1/2活性的影响[J].陕西医学杂志,2023,52(12):1642.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.004]
　HAO Lisen,PAN Enliang,JI Jingxiu,et al.Effects of SHP2 expression changes on ERK1/2 activity in liver tissues of rats with hepatic fibrosis[J].,2023,52(7):1642.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.004]
[6]徐志刚,曹 罡,程传涛,等.CTRP3通过TGF-β1/Smad 信号通路减弱肝星状细胞活性机制研究*[J].陕西医学杂志,2020,49(5):523.
　XU Zhigang,CAO Gang,CHENG Chuantao,et al.Mechanism of CTRP3 attenuating hepatic stellate cell activation through TGF-β1/Smad signal pathway[J].,2020,49(7):523.
[7]刘 俊,曾 龙,高 云,等.长链非编码RNA YAF2-AS1通过调控微小RNA-141-3p表达抑制肝星状细胞活化实验研究[J].陕西医学杂志,2023,52(9):1120.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.002]
　LIU Jun,ZENG Long,GAO Yun,et al.Long-chain non-coding RNA YAF2-AS1 inhibits activation of hepatic stellate cells by regulating expression of microRNA-141-3p[J].,2023,52(7):1120.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.002]

备注/Memo

备注/Memo:
*国家自然科学基金资助项目(81660779)；广西一流学科建设项目重点课题(2018XK035)；广西创新驱动发展专项(2017AA21041)
更新日期/Last Update: 2020-07-28